Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review).
Simpson
D M
DM
Gracies
J-M
JM
Graham
K
K
Hallett
M
M
Miyasaki
J
J
Naumann
M
M
Russman
B
B
Simpson
L
L
So
Y
Y
D001905:Botulinum Toxins / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018908:Muscle Weakness / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000294:innervation / Q000503:physiopathology; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care; D012021:Reflex, Abnormal / Q000187:drug effects / Q000502:physiology; D015203:Reproducibility of Results
D009465:Neuromuscular Agents; D001905:Botulinum Toxins